Submit Manuscript  

Article Details


CD28: A New Drug Target for Immune Disease

Author(s):

Sijing Xia, Qin Chen and Bing Niu*   Pages 1 - 10 ( 10 )

Abstract:


Background: CD28, a cell surface glycoprotein receptor, predominantly expressed on activated T cells, belongs to the Ig superfamily and can provides a critical co-stimulatory signal. CTLA-4 has sequence homology to CD28, is expressed on T cells after activation. It provides an inhibition signal coordinated with CD28 to regulate T cell activation. Both of them regulate T cell proliferation and differentiation, and play an important role in the immune response pathway in vivo.

Objective: We studied the special role of different structural sites of CD28 in producing costimulatory signals.

Method: We reviewed the relevant literature, mainly from the structure of CD28 to clarify its biological function, and its role in the immune response.

Results: In recent years, increasingly attention has been paid to CD28, which is considered as a key therapeutic target for many modern diseases, especially some immune diseases.

Conclusion: In this paper, we mainly introduce the structure of CD28 and its related biological functions, as well as the application of costimulatory pathways targeting CD28 in disease treatment.

Keywords:

Ligands , CTLA-4, Structure, Immune Response, Transplant rejection, Malignant tumor, Systemic lupus erythematosus, Rheumatoid arthritis Ligands, Rheumatoid arthritis

Affiliation:

College of Life Science, Shanghai University, Shanghai, College of Life Science, Shanghai University, Shanghai, College of Life Science, Shanghai University, Shanghai



Read Full-Text article